Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options

TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to... Purpose: Currently, there are only a few software tools designed to assist physicians to translate molecular abnormalities in the cancer genome into potential treatment options. There is a pressing need to develop software to reliably identify known targeted therapies and experimental treatments for patients on the basis of the results of tumor DNA sequencing. Methods: The TQuest platform includes a data layer, data acquisition layer, search engine, and user interface. It identifies associations between one or more molecular targets and therapeutic options. The data layer consists of indexed interventional clinical trials and an expert-curated database of clinically or experimentally validated associations between mutations and drug response. The data acquisition layer includes an information-harvesting module that keeps an up-to-date full-text index of clinical trials by crawling clinicaltrials.gov and combining it with US Food and Drug Administration label data. The user interface is a Web-based module that allows users to upload genomic variants, tumor morphology, and diagnosis. The search results are qualified and ranked by a relevance score. Results: We have manually curated information for 368 distinct genomic variants of 162 gene targets corresponding to 863 drug and target interactions. The platform currently contains a full-text index of approximately 80,000 interventional clinical trials. We applied TQuest to molecular data from 73 metastatic breast cancers. TQuest identified a total of 276 drugs as potential therapeutic options, ranging from one to 103 per patient. Conclusion: TQuest correctly identified all US Food and Drug Administration-approved drugs and routine indications for all cases and also identified many additional drugs that were used in the context of a given molecular abnormality in various clinical trials. The prototype Web application is available at www.tquest.us, and the source code is open and available on GitHub. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JCO Clinical Cancer Informatics Wolters Kluwer Health

TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options

Download PDF
13 pages

Loading next page...
 
/lp/wolters-kluwer-health/tquest-a-web-based-platform-to-enable-precision-medicine-by-linking-a-0iKYwN0IqV
Publisher
Wolters Kluwer Health
Copyright
(C) 2018 by Lippincott Williams & Wilkins, Inc.
ISSN
2473-4276
DOI
10.1200/CCI.17.00120
Publisher site
See Article on Publisher Site

Abstract

Purpose: Currently, there are only a few software tools designed to assist physicians to translate molecular abnormalities in the cancer genome into potential treatment options. There is a pressing need to develop software to reliably identify known targeted therapies and experimental treatments for patients on the basis of the results of tumor DNA sequencing. Methods: The TQuest platform includes a data layer, data acquisition layer, search engine, and user interface. It identifies associations between one or more molecular targets and therapeutic options. The data layer consists of indexed interventional clinical trials and an expert-curated database of clinically or experimentally validated associations between mutations and drug response. The data acquisition layer includes an information-harvesting module that keeps an up-to-date full-text index of clinical trials by crawling clinicaltrials.gov and combining it with US Food and Drug Administration label data. The user interface is a Web-based module that allows users to upload genomic variants, tumor morphology, and diagnosis. The search results are qualified and ranked by a relevance score. Results: We have manually curated information for 368 distinct genomic variants of 162 gene targets corresponding to 863 drug and target interactions. The platform currently contains a full-text index of approximately 80,000 interventional clinical trials. We applied TQuest to molecular data from 73 metastatic breast cancers. TQuest identified a total of 276 drugs as potential therapeutic options, ranging from one to 103 per patient. Conclusion: TQuest correctly identified all US Food and Drug Administration-approved drugs and routine indications for all cases and also identified many additional drugs that were used in the context of a given molecular abnormality in various clinical trials. The prototype Web application is available at www.tquest.us, and the source code is open and available on GitHub.

Journal

JCO Clinical Cancer Informatics – Wolters Kluwer Health

Published: Jun 1, 2018

References

  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
    Bang YJ; Van Cutsem E; Feyereislova A
  • Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
    Capdeville R; Buchdunger E; Zimmermann J
  • Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
    Joensuu H; Roberts PJ; Sarlomo-Rikala M
  • Identifying health information technology needs of oncologists to facilitate the adoption of genomic medicine: Recommendations from the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop
    Hughes KS; Ambinder EP; Hess GP
  • Rapid learning for precision oncology
    Shrager J; Tenenbaum JM
  • Clinical application of high-throughput genomic technologies for treatment selection in breast cancer
    Hansen AR; Bedard PL
  • Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
    Le Tourneau C; Delord JP; Goncalves A
  • Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials
    Meric-Bernstam F; Brusco L; Shaw K
  • Big data: The power of petabytes
    Eisenstein M
  • Cancer: Reshaping the cancer clinic
    Schmidt C
  • Identifying the status of genetic lesions in cancer clinical trial documents using machine learning
    Wu Y; Levy MA; Micheel CM
  • Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
    Gao J; Aksoy BA; Dogrusoz U
  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
    Zehir A; Benayed R; Shah RH
  • Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells
    Yang W; Soares J; Greninger P
  • DGIdb 2
    Wagner AH; Coffman AC; Ainscough BJ
  • Mutation based treatment recommendations from next generation sequencing data: A comparison of web tools
    Patel JM; Knopf J; Reiner E
  • Enhancing next-generation sequencing-guided cancer care through cognitive computing
    Patel NM; Michelini VV; Snell JM
  • Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial
    Andre F; O'Regan R; Ozguroglu M
  • NoSQL database: New era of databases for big data analytics-classification, characteristics and comparison
    Moniruzzaman AB; Hossain SA
  • TQuest
    Pathology Informatics & Breast Medical Oncology Bioinformatics